Why Bruker Stock Slumped Monday
Key Points
It flipped to a GAAP net loss in its third quarter, although on a non-GAAP basis it was in the black.
It beat on both the top and bottom lines.
- 10 stocks we like better than Bruker ›
Bruker (NASDAQ: BRKR) published its latest quarterly earnings report Monday morning, and despite notching a double beat the company's stock took something of a hit. Its price fell nearly 1% by the closing bell, as investors didn't take kindly to a double miss on full-year guidance. Earlier in the trading session, Bruker dipped as much as 3.9%.
Strength in niche segments
Bruker, which specializes in the supply of medical devices and scientific instruments, earned revenue of almost $861 million in its third quarter. This number was down 0.5% from the same period of 2024.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
The company's bottom line according to generally accepted accounting principles (GAAP) flipped to a net loss of $62 million, against the nearly $41 million profit in the year-ago quarter. Things looked better on a non-GAAP (adjusted) basis, as Bruker was profitable to the tune of $0.45 per share against third quarter 2024's $0.60 net income.
On average, analysts tracking the company's stock were anticipating revenue of $847 million, and per-share, adjusted net income of $0.33.
Bruker said that it benefited from bookings in the academic and government customer segments during the quarter, in addition to strength in the biotech sector.
Chop, chop
As any seasoned investor knows, however, stocks typically trade on future potential rather than trailing wins.
Bruker lowered its full-year 2025 guidance, and this dimmed the good parts of its earnings release. The company is now forecasting it will book revenue of $3.41 billion to $3.44 billion this year. By comparison, 2024's top line was $3.37.
As for adjusted net income, that guidance has been trimmed to $1.85 to $1.90 per share. That's well down from the 2024 result of $2.41.
Should you invest $1,000 in Bruker right now?
Before you buy stock in Bruker, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bruker wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $593,269!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,268,146!*
Now, it’s worth noting Stock Advisor’s total average return is 1,076% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bruker. The Motley Fool has a disclosure policy.
Recommended Articles
